Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Seth Wander
Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer
Related publications
RING Domain–deficient BRCA1 Promotes PARP Inhibitor and Platinum Resistance
Journal of Clinical Investigation
Medicine
The PARP Inhibitor AZD2281 (Olaparib) Induces Autophagy/Mitophagy in BRCA1 and BRCA2 Mutant Breast Cancer Cells
International Journal of Oncology
Cancer Research
Oncology
PARP Inhibitor Treatment in Ovarian and Breast Cancer
Current Problems in Cancer
Cancer Research
Oncology
Lurbinectedin Is Active in Patients With BRCA1/2 Mutant Breast Cancer
Cancer Discovery
Oncology
Metronomic Chemotherapy in Metastatic Breast Cancer
Novel Research in Sciences
Combination Chemotherapy in Metastatic Breast Cancer
BMJ
Combination Chemotherapy in Metastatic Breast Cancer
InPharma
Alexithymia Reversion in Psoriasis
British Journal of Dermatology
Dermatology
Medicine
PARP Inhibitors in Ovarian Cancer: Sensitivity Prediction and Resistance Mechanisms
Journal of Cellular and Molecular Medicine
Molecular Medicine
Cell Biology